NEW YORK, April 25, 2018 /PRNewswire/ --
WallStEquities.com strives to bring the best free research to the investmentcommunity. Today we are offering reports on AMRN, APRI, DEPO, and DRRX which can be accessed for free by signing up to www.wallstequities.com/registration. Featured today on WallStEquities.com are Amarin Corp. PLC (NASDAQ: AMRN), Apricus Biosciences
On Tuesday, shares in Dublin, Ireland-based Amarin Corp. PLC recorded a trading volume of 3.85 million shares, which was above their three months average volume of 2.16 million shares. The stock ended at $2.79, declining 1.06% from the last trading session. The Company's shares are trading below their 50-day moving average by 15.66%. Furthermore, shares of Amarin, which focuses on the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the US, have a Relative Strength Index (RSI) of 34.96.
On April 23rd, 2018, Amarin announced that Aaron Berg has been promoted to the position of Senior Vice President, Chief Commercial Officer. Mr. Berg previously served the Company as Senior Vice President - Marketing and Sales. Get the full research report on AMRN for free by clicking below at: www.wallstequities.com/registration/?symbol=AMRN
San Diego, California headquartered Apricus Biosciences Inc.'s stock finished yesterday's session 3.70% lower at $0.26 with a total trading volume of 315,466 shares. The stock is trading below their 50-day moving average by 69.68%. Shares of the Company, which focuses on the development of product candidates in the areas of urology and rheumatology, have an RSI of 22.68.
On April 04th, 2018, Apricus Biosciences announced the closing of its previously announced public offering of an aggregate of approximately 7.1 million shares of common stock at a price to the public of $0.50 per share. Investors also received warrants to purchase up to an aggregate of approximately 3.55 million shares of common stock, with an exercise price of $0.50 per share. The offering closed on April 02nd, 2018. The free technical report on APRI can be accessed at: www.wallstequities.com/registration/?symbol=APRI
At the close of trading on Tuesday, shares in Newark, California headquartered Depomed Inc. rose slightly by 0.59%, ending the day at $6.83. The stock recorded a trading volume of 1.35 million shares, which was above its three months average volume of 1.22 million shares. The Company's shares have advanced 8.07% in the last month. The stock is trading 0.46% below its 50-day moving average. Moreover, shares of Depomed, which engages in the development, sale, and licensing of products for pain and other central nervous system conditions in the US, have an RSI of 49.57.
On April 17th, 2018, Depomed announced the appointment of John B. Thomas as Senior Vice President - Investor Relations and Corporate Communications, effective immediately. Mr. Thomas most recently served as Executive Vice President - Corporate Strategy and Investor Relations at Horizon Pharma. Sign up for free on Wall St. Equities and claim the latest report on DEPO at: www.wallstequities.com/registration/?symbol=DEPO
Cupertino, California headquartered DURECT Corp.'s shares ended the day 0.48% lower at $2.06 with a total trading volume of 443,893 shares. The stock has gained 64.80% over the previous three months and 131.05% over the past year. The Company's shares are trading 11.69% above their 50-day moving average and 38.02% above their 200-day moving average. Additionally, shares of DURECT, which researches and develops medicines based on its epigenetic regulator and drug delivery programs, have an RSI of 45.43. See the free research coverage on DRRX at: www.wallstequities.com/registration/?symbol=DRRX
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: +21-32-044-483Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/quotidian-technical-highlights-on-selected-drug-makers-stocks----amarin-apricus-biosciences-depomed-and-durect-300636190.html
SOURCE Wall St. Equities
Subscribe to our Free Newsletters!
True vertigo is a severe form of dizziness that is a movement hallucination. Try out some of these ...
Oxidative stress is a form of injury to body tissues due to increase in free radicals. If the ...
Graviola's health benefits range from curing headaches to fighting cancer. Read on to know more ...View All